hydroxide ion

Subscribe to Selected New Research on hydroxide ion

4866 relevant articles (210 outcomes, 624 trials/studies) found for this Bio-Agent

Also Known As:

OH-; hydroxide; hydroxyl ion

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 5

Experts

1.	Su, M-C: 3 articles (08/2007 - 03/2005)
2.	Michael, J V: 3 articles (08/2007 - 03/2005)
3.	Srinivasan, N K: 3 articles (08/2007 - 03/2005)
4.	Geisser, Peter: 3 articles (01/2007 - 01/2007)
5.	Potgieter, Maria A: 3 articles (01/2007 - 01/2007)
6.	Venter, Cornea: 3 articles (01/2007 - 01/2007)
7.	Venter, Jan L: 3 articles (01/2007 - 01/2007)
8.	Potgieter, Johannes H: 2 articles (01/2007 - 01/2007)
9.	Knerer, Birgit: 2 articles (09/2006 - 01/2004)
10.	Formanek, Michael: 2 articles (09/2006 - 01/2004)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1981 - "OH-BBN administration schedule had a significant effect on cancer incidence: administration of a total dose of 30, 20, or 15 mg OH-BBN in 20 weekly fractions was more effective in cancer induction than was the same total dose given in 5 fractions" 12/23/1994 - "Although [3H]OCT administered intravenously into FA-6 tumor-bearing nude mice was cleared from the circulation more rapidly than [3H]1,25-(OH)2D3, the uptake of [3H]OCT into the tumor tissue, relative to the radioactivity in the circulation, was greater than that of [3H]1,25-(OH)2D3" 02/01/2007 - "Some compounds of Cephalostatin family have shown anti-cancer activity against human cancer cell line and active intensity has close with the stereochemistry of the substituted group, for example, beta-OH at C-12 in compound 2 showed less promising results and the mixture 3 (alpha + beta) showed a large enhancement of the activity compared to the compound 2. So, the work was concentrated on the synthesis diastereomers 10 and 11 were obtained in a pure form." 11/01/2008 - "Dose-response clonogenic studies showed that all six analogs had greater antiproliferative activities against cancer cells than 1,25(OH)(2)D(3)" 04/01/2007 - "In vitro and in vivo studies have shown that 1alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] inhibits angiogenesis in cancer" Get all the results and reference details, order at left...
2.	Secondary Hyperparathyroidism 07/01/1994 - "The aim of this double blind, comparative, randomized study was to eveluate the efficacy of treatment with 1-alpha-OHD3 plus 24,25(OH)2D3 in patients with secondary hyperparathyroidism.A group of 46 patients, 26 females and 20 males, aged 19-67, on chronic haemodialysis, was examined" 12/01/1993 - "Conflicting results have been reported regarding the efficacy of intermittent versus continuous administration of 1,25(OH)2D3 in renal secondary hyperparathyroidism" 10/01/1989 - "It is concluded that 3 g/day CaCO3 is equivalent to 2 g/day Al(OH)3 in terms of its phosphate-binding effect, and the prescription of CaCO3 together with 1 alpha (OH)D3 ameliorates secondary hyperparathyroidism." 07/01/2004 - "The aim of the study was to investigate the influence of 1,25(OH)2D3 therapy on long-term control of glycemia in hemodialyzed (HD) patients with severe secondary hyperparathyroidism (SHP)" 01/01/2003 - "In agreement with this new classification, in a recent study conducted in a random sample of our population, a high prevalence of low levels of 25(OH)D and secondary hyperparathyroidism was found" Get all the results and reference details, order at left...
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/1990 - "1,24R(OH)2D3 may be useful in the treatment of psoriasis." 10/01/2007 - "CONCLUSION: UVB therapy in elderly psoriatic women improved psoriasis, increased serum 25(OH)D3 synthesis and reduced serum PTH concentrations." 12/01/1986 - "Controlled trials of large numbers of patients with psoriasis vulgaris treated with 1 alpha(OH)D3 are under way." 02/01/2003 - "1,25(OH)(2)D and its analogs have been developed for treating the hyperproliferative disease psoriasis" 06/01/2001 - "1 alpha,25-Dihydroxyvitamin D(3) (1 alpha,25(OH(2))D(3)) and its analogs are used to treat psoriasis because of their potent antiproliferative activity" Get all the results and reference details, order at left...
4.	Prostatic Neoplasms (Prostate Cancer) 03/01/2005 - "Although not entirely consistent, some studies suggest that higher circulating 1,25(OH)2D may be more important than 25(OH)D for protection against aggressive, poorly-differentiated prostate cancer" 03/01/2001 - "We provide preliminary evidence that 1alpha,25(OH)(2)D(3) may be effective in slowing the rate of PSA rise in selected cases of prostate cancer" 04/01/2007 - "In most studies, 1,25(OH)2D plasma level was not found to be reduced in patients with prostate cancer" 03/01/2007 - "Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk" 03/01/2007 - "The objective of this study is to investigate the influence of 1alpha,25(OH)(2)D(3) and PUFAs in the form of fish oil applied alone or in combination on cell cycle kinetics in the exponentially growing androgen-dependent and -independent prostate cancer cells" Get all the results and reference details, order at left...
5.	Osteoporosis 12/01/2004 - "The levels of OC, BAP, CTx, PTH and 1,25(OH)2D were significantly greater for women with osteoporosis than for those without" 11/20/1989 - "From the above, it was suggested that 1,25(OH)2D3 might be effective for the treatment of senile osteoporosis especially at the dose of 0.5 microgram/day." 11/01/2007 - "The aim of the present study was to evaluate serum 25(OH)D and its relationship with nutrient intakes in postmenopausal Brazilian women with osteoporosis" 01/01/2002 - "Enrolled in the present study were 16 elderly osteoporosis women aged 72.6 +/- 4.5 years to whom 1 microgram of 1 alpha(OH)D3 was administered daily" 11/20/1989 - "The effect of 1,25(OH)2D3 on bone mineral content in senile osteoporosis--a dose-finding study]" Get all the results and reference details, order at left...
782 Diseases and 4866 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Vitamin D
2.	Calcitriol (Calcijex)
3.	Calcium
4.	Cholecalciferol (Vitamin D3)
5.	Doxorubicin (Adriamycin)
6.	Parathyroid Hormone (Parathormone)
7.	Phosphorus (Red Phosphorus)
8.	1-hydroxycholecalciferol (alfacalcidol)
9.	Cyclophosphamide (Cytoxan)
10.	DNA (Deoxyribonucleic Acid)
1713 Drugs and Important Bio-Agents and 3436 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Drug Therapy (Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Heterologous Transplantation (Xenotransplantation)
5.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
97 Therapies and Procedures and 284 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>